← Back to Search

Hormone Therapy

Concurrent Endocrine Therapy and Radiotherapy for Breast Cancer (REaCT-RETT Trial)

Phase 4
Waitlist Available
Led By Sharon McGee, MD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months (+/- 2 weeks) post final fraction of radiotherapy
Awards & highlights

REaCT-RETT Trial Summary

This study is evaluating whether a type of treatment for breast cancer is more effective than another type of treatment.

Eligible Conditions
  • Breast Cancer

REaCT-RETT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months (+/- 2 weeks) post final fraction of radiotherapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months (+/- 2 weeks) post final fraction of radiotherapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Endocrine toxicity
Secondary outcome measures
Direct Estimation of Health Utility Values
Exploratory analyses on evaluating radiotherapy toxicity
Incremental cost-effectiveness ratios
+2 more

REaCT-RETT Trial Design

2Treatment groups
Active Control
Group I: Concurrent Endocrine Therapy and RadiotherapyActive Control1 Intervention
Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
Group II: Sequential Endocrine Therapy after RadiotherapyActive Control1 Intervention
Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,429 Total Patients Enrolled
35 Trials studying Breast Cancer
5,261 Patients Enrolled for Breast Cancer
Sharon McGee, MDPrincipal InvestigatorOttawa Hospital Research Institute
3 Previous Clinical Trials
287 Total Patients Enrolled
3 Trials studying Breast Cancer
287 Patients Enrolled for Breast Cancer
Jean Marc Bourque, MDPrincipal InvestigatorOttawa Hospital Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)
2019. "Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03948568.
~47 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top